Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.44 |
| ▸ | CCNC | P24863 | 4/20 | 0.41 |
| ▸ | CDK8 | P49336 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578747 | 0.89 | SLC22A12 (0.46) | CYP1A2CYP2D6CYP2C19SLC22A12CCNC | |
| SCHEMBL578953 | 0.88 | SLC22A12 (0.45) | SLC22A12CCNCCDK8 | |
| SCHEMBL578297 | 0.87 | SLC22A12 (0.41) | SLC22A12CCNCCDK8 | |
| SCHEMBL578413 | 0.86 | SLC22A12 (0.43) | SLC22A12CCNCCDK8 | |
| SCHEMBL578723 | 0.81 | SLC22A12 (0.39) | CYP3A4SLC22A12CCNCCDK8 | |
| SCHEMBL618500 | 0.81 | SLC22A12 (0.39) | CYP3A4SLC22A12CCNCCDK8 | |
| SCHEMBL578695 | 0.80 | SLC22A12 (0.38) | SLC22A12CCNCCDK8 | |
| SCHEMBL578334 | 0.80 | ACVR1 (0.48) | SLC22A12CCNCCDK8CHEK1 | |
| SCHEMBL578333 | 0.79 | MAP4K4 (0.61) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1316267 | 0.79 | KDM4E (0.39) | CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | CYP11B1 1332/4885CYP11B2 1520/4885CYP1A2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.